22 February 2017 Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes
Author Affiliations +
Abstract
The highly used cancer imaging technique, [18F]FDG-PET, is based on the increased glucose metabolic activity in tumors. However, since there are other biological processes that exhibit increased metabolic activity, in particular inflammation, this methodology is prone to non-specificity for cancer. Herein we describe the development of a novel nanoparticle-based approach, utilizes Glucose-Functionalized Gold Nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our method has demonstrated specific tumor targeting and has successfully differentiated between cancer and inflammation in a combined tumor-inflammation mouse model, due to dissimilarities in vasculatures in different pathologic conditions. This novel approach provides new capabilities in cancer imaging, and can be applicable to a wide range of cancers.
Conference Presentation
© (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Tamar Dreifuss, Tamar Dreifuss, Menachem Motiei, Menachem Motiei, Oshra Betzer, Oshra Betzer, Aron Popovtzer, Aron Popovtzer, Galith Abourbeh, Galith Abourbeh, Eyal Mishani, Eyal Mishani, Rachela Popovtzer, Rachela Popovtzer, } "Glucose-functionalized gold nanoparticles as a metabolically targeted CT contrast agent for distinguishing tumors from non-malignant metabolically active processes", Proc. SPIE 10077, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XIV, 100770I (22 February 2017); doi: 10.1117/12.2249850; https://doi.org/10.1117/12.2249850
PROCEEDINGS
9 PAGES + PRESENTATION

SHARE
Back to Top